KMC Speciality Hospitals (India) Ltd

Capacity: ~330 census beds operational across the Trichy cluster (250 main + 200-bed Maa Kauvery at ~early ramp). Q3FY26 occupancy ran at ~82% with ~18% IPD-volume growth — indicating the new beds are filling faster than feared, the key driver of FY26's operating-leverage step-up.

Strategic priorities: (1) ramp Maa Kauvery toward mature-asset margins; (2) deepen high-acuity specialty mix to lift ARPOB; (3) deleverage as expansion capex tails off; (4) evaluate measured capacity additions in the Kauvery footprint.

India's private hospital sector is a structural multi-decade theme: rising insurance penetration (Ayushman Bharat + private health cover), under-bedded tier-2/3 cities (India ~1.3 beds/1,000 vs WHO norm ~3), medical-tourism inflows, and a shift of complex care from metros to affordable regional hubs. The listed hospital basket has consequently re-rated to 30–40x EV/EBITDA.

Capacity: 450 operational beds (250 legacy + 200 Maa Kauvery); 330 census, ~270 occupied (Q3FY26) = 82% occupancy with +18% IPD and +32% OPD volume growth. Payor mix is healthy and cash-led: 69% cash / 22% TPA-corporate / 9% government scheme — low scheme dependence keeps the debtor cycle at ~9 days. Customer concentration is low (fragmented patients), but ~92% of in-patients come from Trichy and its immediate catchment — geographic concentration is the key operational risk, and the new block deepens rather than diversifies it.

Revenue compounded from ₹103 Cr (FY21) to ₹306 Cr (FY26), a ~24% CAGR, with FY26 growth accelerating to ~32% as Maa Kauvery filled. The FY25 PAT dip to ₹21 Cr was not an operational miss — it reflected the step-up in interest (₹10 Cr) and depreciation (₹19 Cr) from commissioning the new facility. FY26 confirms the recovery: PAT ₹47 Cr (+124% YoY), OPM back to 29%.

Upcoming triggers to watch: any TN/central move on procedure price-capping or insurance-reimbursement rate revisions; these are the principal regulatory swing factors for hospital margins.

Institutional sell-side coverage of KMC is thin given its micro-cap size; the stock is tracked mainly by smallcap-focused desks and retail research (e.g. Sana Securities, MarketsMojo). The recurring analyst debate centres on execution of the new-hospital ramp and whether the "Trichy Model" is replicable beyond the home catchment. Consensus themes: strong balance sheet, sector-leading ROCE, and a valuation discount to large-cap peers that should narrow if growth sustains.

Source: public analyst reports & India Ratings press releases — research framing only, not a recommendation.

Capex peaked in FY24–FY25 (the new facility build); FY26 shows borrowings declining and reserves building — deleveraging has begun. Operating cash flow has consistently tracked ~100%+ of operating profit (CFO/OP: 101% FY24, 112% FY25) — a strong earnings-quality signal. FCF was negative in the build years (FY24 −₹37 Cr) purely due to growth capex, not working-capital stress.

Fraud / Earnings-Quality Filter

On FY26 EPS of ₹2.87, KMC trades at ~35x P/E and ~19–20x EV/EBITDA — the lowest multiples in the listed hospital peer set, despite posting the highest ROCE. The discount reflects micro-cap liquidity and single-geography risk; the bull case is multiple convergence toward peers as scale and replication are demonstrated.

Own-history read: KMC has re-rated from ~20x to ~35x over two years as growth and the IND AA- upgrade landed. At 35x it is no longer cheap on absolute terms, but remains the cheapest in a structurally premium-rated sector. Peer multiples for research context only — not a recommendation.

For a hospital, the analogue of an order book is occupancy × ARPOB × bed count — the throughput pipeline. KMC's leading indicators are all trending up.

Payor mix (Q3FY26): Cash 69% · TPA/Corporate 22% · Government scheme 9% — a high-quality, largely cash-and-insurance book with minimal government-receivable drag. Specialty mix: Mother & Child 27%, Neurosciences 18%, Gastrosciences 12%, with Critical Care, Ortho, Renal and General Medicine each ~6–7% — diversified across high-acuity lines, reducing single-specialty dependence.

Management / promoter: Backed by the Kauvery Hospitals group (Dr S Chandrakumar & founding clinicians), a respected Tamil Nadu healthcare franchise. Promoter holding is a high, stable 75% — strong alignment. Capital allocation has been disciplined: growth capex funded with modest debt (D/E 0.40x), no dividend yet (reinvesting), and the credit upgrade validates the financing approach.

Guidance-accuracy read: Credible (>75%). The FY26 execution closely tracked the new-facility-ramp narrative management had set out. Caveat: KMC discloses less granular forward guidance than large-caps, so the scorecard rests on directional delivery rather than precise numeric targets.

RESEARCH TRACKING MILESTONES — NOT INVESTMENT SIGNALS

Shareholding detail beyond promoter/public split is limited on the free data tier — verify granular FII/DII on Screener.in / BSE filings.

SCENARIO ANALYSIS — FOR RESEARCH REFERENCE ONLY. NOT AN INVESTMENT RECOMMENDATION. Primary metric: P/E (profitable, capex-tailing healthcare service); EV/EBITDA cross-checked. Multiples anchored to KMC's own re-rated history and the (much higher) peer set.

What to watch (links to A14): Maa Kauvery occupancy >85%, any new-cluster announcement, OPM holding ≥29%. These milestones are research tracking signals — not signals to act.

Stage 2 (Mark-up). KMC spent Jun–Oct 2025 basing in a ₹63–70 range (Stage 1 accumulation), then broke out in Nov-2025 on heavy volume, stepped up again in Jan-2026 (₹85–90), consolidated through Feb–Apr, and surged to a fresh all-time high of ₹103.9 on 29-May-2026. The structure is higher-highs / higher-lows — a clean Stage-2 uptrend with a breakout-to-new-highs setup.

Price (₹100.5) sits well above its 50-DMA (~₹89.6) and 200-DMA (~₹80.9), with 50>200 (bullish alignment / golden-cross structure intact). Weekly moving-average score 0.93 (strong); oscillator score a modest +0.18 — momentum is strong but not screaming overbought, leaving room. Volume confirms: the largest up-days (Oct-6 0.77M, Nov-12 0.84M, May-8 0.46M, May-29 0.77M) came on advances with healthy delivery %, the signature of accumulation rather than churn.

All levels are Research Reference Levels — not buy/sell signals.

KMC has been a clear out-performer — up ~60% from its mid-2025 base while broader small-caps were range-bound. On the TradingView peer TA scan it ranks alongside Rainbow at the top of the hospital basket on weekly signals:

⚠ For research reference only. These are not buy/sell recommendations.

Bullish confirmation: a weekly close decisively above ₹104 on above-average volume would open blue-sky continuation. Invalidation: a weekly close below the 200-DMA (~₹80) would break the Stage-2 structure. Calendar catalyst: Q1FY27 results (~Aug 2026) — the first read on whether the FY26 margin step-up is sustained.

This document is a research and educational output only, generated by the Primaegis Research Investment Analysis Pipeline. Neither Ameya Pimpalgaonkar nor any contributor to this report is a SEBI registered investment advisor or research analyst. Nothing herein constitutes investment advice, a research recommendation, or a solicitation to buy, sell, or hold any security under SEBI (Research Analyst) Regulations, 2014 or any other applicable law. All financial data is sourced from publicly available disclosures (Screener.in, India Ratings, BSE/NSE filings, company releases). All technical levels are reference levels for research tracking only. Always conduct your own due diligence and consult a SEBI registered investment advisor before making any financial decision.

Generated: 31 May 2026 · Primaegis Research · Not for distribution.